TrialESMO open2021

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.

L Paz-Ares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.